1. Home
  2. NYXH vs EDAP Comparison

NYXH vs EDAP Comparison

Compare NYXH & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.50

Market Cap

190.6M

Sector

Health Care

ML Signal

HOLD

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.35

Market Cap

163.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYXH
EDAP
Founded
2009
1979
Country
Belgium
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.6M
163.4M
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
NYXH
EDAP
Price
$3.50
$3.35
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$11.25
$2.00
AVG Volume (30 Days)
53.1K
37.7K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$70,527,000.00
Revenue This Year
$214.32
N/A
Revenue Next Year
$124.13
$10.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.63
52 Week Low
$2.76
$1.21
52 Week High
$8.64
$5.05

Technical Indicators

Market Signals
Indicator
NYXH
EDAP
Relative Strength Index (RSI) 53.12 35.06
Support Level N/A $3.32
Resistance Level $5.02 $3.44
Average True Range (ATR) 0.17 0.31
MACD 0.07 -0.04
Stochastic Oscillator 95.32 25.12

Price Performance

Historical Comparison
NYXH
EDAP

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: